Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.
Authors
Brundage, MSydes, M
Parulekar, W
Warde, P
Cowan, Richard A
Bezjak, A
Kirkbride, P
Parliament, M
Moynihan, C
Bahary, J
Parmar, M
Sanders, K
Chen, B
Mason, M
Affiliation
Queen's Cancer Research Institute and Cancer Centre of Southeastern OntarioIssue Date
2015-05-26
Metadata
Show full item recordAbstract
The NCIC CTG PR3/MRC PR07 randomized phase III trial compared androgen-deprivation therapy (ADT) alone versus ADT with radiotherapy (RT) for patients with locally advanced prostate cancer. This article reports the health-related quality-of-life (HRQOL) outcomes of this trial.Citation
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. 2015: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2014.57.8724PubMed ID
26014295Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2014.57.8724
Scopus Count
Collections
Related articles
- Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
- Authors: Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P
- Issue date: 2015 Jul 1
- Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
- Authors: Vargas CE, Alam NB, Terk M, Niska JR, Cesaretti J, Swartz D, Vashi A, Kasraeian A, West CS, Blasser M, Moore C
- Issue date: 2019
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
- Authors: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG PR.3/MRC UK PR07 investigators.
- Issue date: 2011 Dec 17
- Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
- Authors: Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Garant MP, Souhami L
- Issue date: 2018 Oct
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
- Authors: Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K
- Issue date: 2018 Feb